Multiplex assay reliability and long-term intra-individual variation of serologic inflammatory biomarkers

Cytokine

Volumn 90, Issue , 2017, Pages 185-192

  McKay, Heather S ^a   Margolick, Joseph B ^a   Martínez Maza, Otoniel ^b,c,d   Lopez, Joseph ^a   Phair, John ^e   Rappocciolo, Giovanna ^f   Denny, Thomas N ^g   Magpantay, Larry I ^b   Jacobson, Lisa P ^a   Bream, Jay H ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammatory biomarkers; Intraclass correlation; Multiplex assay reliability; Reliability

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; CD14 ANTIGEN; CD27 ANTIGEN; CHEMOKINE; CXCL13 CHEMOKINE; CYTOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN GP 130; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; AUTACOID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; RELIABILITY; SEROLOGY; BLOOD; CLINICAL TRIAL; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTICENTER STUDY; MULTIPLEX POLYMERASE CHAIN REACTION;

BIOMARKERS; CYTOKINES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION MEDIATORS; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES;

EID: 85002518514     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.09.018     Document Type: Article

References (37)

1. [1] Moss, S.F., Blaser, M.J., Mechanisms of disease: inflammation and the origins of cancer. Nat. Clin. Pract. Oncol. 2:2 (2005), 90–97 (quiz 1 p following 113).
2. [2] Heikkila, K., et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control: CCC 20:1 (2009), 15–26.
3. [3] Klingenberg, R., Hansson, G.K., Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur. Heart J. 30:23 (2009), 2838–2844.
4. [4] Silverstein, D.M., Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediat. Nephrol. 24:8 (2009), 1445–1452.
5. [5] Tilg, H., The role of cytokines in non-alcoholic fatty liver disease. Dig. Dis. 28:1 (2010), 179–185.
6. [6] Appay, V., Sauce, D., Immune activation and inflammation in HIV-1 infection: causes and consequences. J. Pathol. 214:2 (2008), 231–241.
7. [7] Chaturvedi, A.K., et al. Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study. Cancer Epidemiol., Biomarkers Prevent.: A Publ. Am. Assoc. Cancer Res., Cosponsored Am. Soc. Prevent. Oncol. 20:9 (2011), 1902–1911.
8. [8] Agalliu, I., et al. Detectability and reproducibility of plasma levels of chemokines and soluble receptors. Results Immunol. 3 (2013), 79–84.
9. [9] Fitzmaurice, G.M., Laird, N.M., Ware, J.H., Applied Longitudinal Analysis. WIley Series in Probability and Statistics. 2004, John Wiley & Sons, Inc., Hoboken 506.
10. [10] Galai, N., et al. Tracking of markers and onset of disease among HIV-1 seroconverters. Stat. Med. 12:22 (1993), 2133–2145.
11. [11] Gu, Y., et al. Reproducibility of serum cytokines and growth factors. Cytokine 45:1 (2009), 44–49.
12. [12] Hofmann, J.N., et al. Intra-individual variability over time in serum cytokine levels among participants in the prostate, lung, colorectal, and ovarian cancer screening Trial. Cytokine 56:2 (2011), 145–148.
13. [13] Clendenen, T.V., et al. Temporal reliability of cytokines and growth factors in EDTA plasma. BMC Res. Notes, 3, 2010, 302.
14. [14] Linkov, F., et al. Reliability of tumor markers, chemokines, and metastasis-related molecules in serum. Eur. Cytokine Netw. 20:1 (2009), 21–26.
15. [15] Navarro, S.L., et al. Reliability of serum biomarkers of inflammation from repeated measures in healthy individuals. Cancer Epidemiol., Biomarkers Prevent.: A Publ. Am. Assoc. Cancer Res., Cosponsored Am. Soc. Prevent. Oncol. 21:7 (2012), 1167–1170.
16. [16] Lee, S.A., et al. Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies. Cancer Epidemiol., Biomarkers Prevent.: A Publ. Am. Assoc. Cancer Res., Cosponsored Am. Soc. Prevent. Oncol. 16:11 (2007), 2464–2470.
17. [17] Kaplan, R.C., et al. Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiol., Biomarkers Prevent.: A Publ. Am. Assoc. Cancer Res., Cosponsored Am. Soc. Prevent. Oncol. 16:6 (2007), 1291–1293.
18. [18] Platz, E.A., et al. Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies. Cancer Causes Contr.: CCC 21:6 (2010), 847–851.
19. [19] Wong, H.L., et al. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol., Biomarkers Prevent.: A Publ. Am. Assoc. Cancer Res., Cosponsored Am. Soc. Prevent. Oncol. 17:12 (2008), 3450–3456.
20. [20] Epstein, M.M., et al. Temporal stability of serum concentrations of cytokines and soluble receptors measured across two years in low-risk HIV-seronegative men. Cancer Epidemiol., Biomarkers Prevent.: A Publ. Am. Assoc. Cancer Res., Cosponsored Am. Soc. Prevent. Oncol. 22:11 (2013), 2009–2015.
21. [21] Kaslow, R.A., et al. Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study. Ann. Intern. Med. 107:4 (1987), 474–480.
22. [22] Chmiel, J.S., et al. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am. J. Epidemiol. 126:4 (1987), 568–577.
23. [23] Cohen, J., A coefficient of agreement for nominal scales. Educ. Psychol. Measur. 20 (1960), 37–46.
24. [24] Rosner, B.A., Fundamentals of Biostatistics, vol. 6, 2006, Brooks/Cole, Thomson.
25. [25] Whitney, C.W., Lind, B.K., Wahl, P.W., Quality assurance and quality control in longitudinal studies. Epidemiol. Rev. 20:1 (1998), 71–80.
26. [26] Dabitao, D., et al. Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array. J. Immunol. Meth. 372:1–2 (2011), 71–77.
27. [27] Tworoger, S.S., Hankinson, S.E., Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis. Cancer Causes Contr.: CCC 17:7 (2006), 889–899.
28. [28] Tworoger, S.S., Hankinson, S.E., Collection, processing, and storage of biological samples in epidemiologic studies: sex hormones, carotenoids, inflammatory markers, and proteomics as examples. Cancer Epidemiol., Biomarkers Prevent.: A Publ. Am. Assoc. Cancer Res., Cosponsored Am. Soc. Prevent. Oncol. 15:9 (2006), 1578–1581.
29. [29] Hankinson, S.E., et al. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol., Biomarkers Prevent.: A Publ. Am. Assoc. Cancer Res., Cosponsored Am. Soc. Prevent. Oncol. 4:6 (1995), 649–654.
30. [30] Rosner, B., Spiegelman, D., Willett, W.C., Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am. J. Epidemiol. 136:11 (1992), 1400–1413.
31. [31] Hsing, A.W., et al. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol., Biomarkers Prevent.: A Publ. Am. Assoc. Cancer Res., Cosponsored Am. Soc. Prevent. Oncol. 16:5 (2007), 1004–1008.
32. [32] Kirby, A.J., Galai, N., Munoz, A., Sample size estimation using repeated measurements on biomarkers as outcomes. Contr. Clin. Trials 15:3 (1994), 165–172.
33. [33] Vendrame, E., et al. Serum levels of cytokines, and biomarkers for inflammation and immune activation, and HIV-Associated Non-Hodgkin B cell Lymphoma Risk. Cancer Epidemiol., Biomarkers Prevent.: A Publ. Am. Assoc. Cancer Res., Cosponsored Am. Soc. Prevent. Oncol., 2013.
34. [34] Breen, E.C., et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol., Biomarkers Prevent.: A Publ. Am. Assoc. Cancer Res., Cosponsored Am. Soc. Prevent. Oncol. 20:7 (2011), 1303–1314.
35. [35] Ho, G.Y., et al. Variability of serum levels of tumor necrosis factor-alpha, interleukin 6, and soluble interleukin 6 receptor over 2 years in young women. Cytokine 30:1 (2005), 1–6.
36. [36] Epstein, M.M., et al. Temporal Stability of Serum Concentrations of Cytokines and Soluble Receptors Measured Across Two Years in Low-Risk HIV-Seronegative Men. Cancer Epidemiol., Biomarkers Prevent.: A Publ. Am. Assoc. Cancer Res., Cosponsored Am. Soc. Prevent. Oncol., 2013.
37. [37] Breen, E.C., et al. Multisite comparison of high-sensitivity multiplex cytokine assays. Clin. Vaccine Immunol.: CVI 18:8 (2011), 1229–1242.